Brain

Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?

HONOLULU, Hawaii, April 05, 2025 (GLOBE NEWSWIRE) -- Arialief is nutritional support specifically designed to offer sciatic nerve relief. It…

6 days ago

University of Arizona Study Finds Openwater’s Open-LIFU 2.0 Device Achieves Significant Depression Symptom Reduction After Less Than Two Hours Total Treatment Time

Clinical Trial Utilizing Low-Intensity Transcranial Focused Ultrasound Pulses to Key Brain Region Shows Notable Reduction in Negative Thoughts, Improved Well-being,…

7 days ago

Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting

Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater…

7 days ago

Sensi.AI and Teepa Snow: In the Moment Care Coaching Is Here

Sensi brings renowned dementia and aging care expert Teepa Snow's proven strategies to the point of care—blending AI with human…

1 week ago

The Lilabean Foundation and CBTN Partner to Accelerate Breakthroughs in Pediatric Brain Cancer Research

WASHINGTON, April 3, 2025 /PRNewswire/ -- The Lilabean Foundation (LBF) is playing a critical role in advancing pediatric brain cancer research…

1 week ago

Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to…

1 week ago

BetterLife Pharma Appoints Corporate Advisor

VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB…

1 week ago

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing…

1 week ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN…

1 week ago

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

1 week ago